Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 2.13 Delayed Data As of Sep 22 |  +0.029 / +1.38%Today’s Change | 0.78 Today|||52-Week Range 5.59 | -40.83% Year-to-Date |
| Previous close | 2.10 |
| Today’s open | 2.27 |
| Day’s range | 2.11 - 2.27 |
| Volume | 706,587 |
| Average volume (3 months) | 2,052,048 |
| Market cap | $34.5M |
| Dividend yield | -- |
| Earnings growth (last year) | +86.71% |
| Earnings growth (this year) | +57.38% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +67.16% |
| P/E ratio | -- |
| Price/Sales | 42.25 |
| Price/Book | 4.43 |
| Today’s change | Today’s % change | |
|---|---|---|
| PRTOProteon Therapeutics... | +0.10 | +6.06% |
| PBMDPrima BioMed Ltd | +0.00 | +0.13% |
| FSIFlexible Solutions I... | -0.02 | -1.16% |
| HTGMHTG Molecular Diagno... | 0.00 | 0.00% |
| Next reporting date | November 8, 2017 |
| EPS forecast (this quarter) | -$0.26 |
| Annual revenue (last year) | $911.0K |
| Annual profit (last year) | -$25.0M |
| Net profit margin | -2,739.74% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer Michael Ward |
Chief Accounting Officer & Vice President-Finance Geneviève Lemaire |
Corporate headquarters Montréal, Quã©bec |
